Alpine ImmunoSciences, L.P. 4
4 · ALPINE IMMUNE SCIENCES, INC. · Filed Jan 22, 2019
Insider Transaction Report
Form 4
Alpine ImmunoSciences, L.P.
10% Owner
Transactions
- Purchase
Warrant (right to buy)
2019-01-18+74,441→ 74,441 totalExercise: $12.74From: 2019-01-18Exp: 2024-01-18→ Common Stock (74,441 underlying) - Purchase
Common Stock
2019-01-18$5.37/sh+190,875$1,024,999→ 3,994,781 total
Footnotes (2)
- [F1]Represents shares acquired in a private placement pursuant to that Securities Purchase Agreement, dated as of January 15, 2019, by and among the Issuer and the Purchasers set forth on the signature pages thereto (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $5.37 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.39 shares of the Company's Common Stock.
- [F2]Alpine BioVentures GP, LLC ("ABV LLC") is the general partner of the Reporting Person. Dr. Mitchell Gold and Dr. Jay Venkatesan are the Managing Partners of ABV LLC. Dr. Gold and Dr. Venkatesan are also limited partners of the Reporting Person. By virtue of their positions as Managing Partners of ABV LLC, Dr. Gold and Dr. Venkatesan may be deemed to have voting and investment power with respect to the shares held by the Reporting Person and as a result may be deemed to have beneficial ownership of such shares. Each of Dr. Gold and Dr. Venkatesan disclaims beneficial ownership of the shares held by the Reporting Person, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, Dr. Gold or Dr. Venkatesan is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.